Benign neoplasm of heart
ICD-10 D15.1 is a billable code used to indicate a diagnosis of benign neoplasm of heart.
Benign neoplasms of the heart are non-cancerous growths that can occur in various structures of the heart, including the myocardium, endocardium, and pericardium. These neoplasms can be asymptomatic or may present with symptoms such as palpitations, chest pain, or heart murmurs, depending on their size and location. Common types of benign heart tumors include myxomas, lipomas, and fibromas. Myxomas, the most prevalent type, often arise in the left atrium and can obstruct blood flow or cause embolic events. Diagnosis typically involves imaging studies such as echocardiography, MRI, or CT scans. While benign, these neoplasms require careful monitoring due to the potential for complications, including obstruction of blood flow or, in rare cases, malignant transformation. Regular follow-up and imaging may be necessary to assess for changes in size or symptoms, guiding treatment decisions which may include surgical intervention if indicated. Understanding the benign nature of these tumors is crucial for appropriate management and patient education.
Detailed imaging reports, clinical notes on symptoms, and treatment plans.
Patients presenting with palpitations or chest pain who undergo echocardiography revealing a mass.
Ensure clear documentation of the tumor's size, location, and any associated symptoms to support coding.
Pathology reports confirming benign nature, treatment notes, and follow-up imaging.
Patients with a known history of benign heart tumors undergoing surveillance imaging.
Documentation must clarify the benign diagnosis to avoid misclassification as malignant.
Used when a benign cardiac tumor is surgically removed.
Operative report detailing the tumor's characteristics and surgical approach.
Cardiology and surgical documentation must align for accurate coding.
Common symptoms may include palpitations, chest pain, shortness of breath, or fatigue, depending on the size and location of the tumor.
Patients should undergo regular follow-up imaging, typically annually or as symptoms dictate, to assess for changes in the tumor's size or behavior.
